ArticleFrontiers in neurology2025
Posterior communicating artery vasospasm impairs cerebral pulsatility in an experimental subarachnoid hemorrhage model.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of glymphatic system in brain injury after subarachnoid hemorrhage.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subarachnoid hemorrhage (SAH) commonly causes cerebral vasospasm and delayed ischemia. Spasm of the posterior communicating artery (PCoA) can disrupt cerebral hemodynamics. We assessed its effect on cerebral pulsatility in a rabbit SAH model, focusing on intracranial pressure pulse amplitude as an early, sensitive marker of vasospasm-driven change, whereas global CBF or neurological outcomes generally require larger or longer studies. Methods: Rabbits were randomly assigned to three groups: control (no injection), sham-controlled (saline injection), and SAH (0.75 mL autologous blood injection into the basal subarachnoid space near the PCoA under anesthesia). Heart rate and cerebral pulsation amplitude (measured via intracranial pressure transducer) were recorded on day 1 and day 7. On day 7, animals were euthanized, and histological analysis of the PCoA was performed. Vasospasm index (VSI) was calculated as the ratio of arterial wall area to lumen area. Group comparisons and temporal changes were assessed statistically. Results: Twenty-three rabbits completed the study (five control, five sham-controlled, 13 SAH, two SAH animals excluded due to early mortality). On day 1, the SAH group showed a significantly reduced pulsation amplitude compared to controls and sham-controlled groups. By day 7, pulsation amplitude partially recovered in the SAH group but remained lower than in controls. Control and sham-controlled groups exhibited a slight, non-significant decline in pulsation. The VSI was highest in the SAH group, moderate in sham-controlled, and lowest in the control groups. Heart rate declined over time across all groups, with significant bradycardia in the SAH group by day 7. Conclusion: PCoA vasospasm following experimental SAH results in a sustained reduction in cerebral pulsatility. These findings suggest that localized vasospasm disrupts pulsatile intracranial dynamics, potentially contributing to SAH-related pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.